Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Unknown 3Terminated 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 3

Conditions

Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Hairy Cell 4Lymphoma, Non-Hodgkin 3Recurrence 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Cerebral Palsy 1

Interventions

Cyclophosphamide 344Cytarabine 281fludarabine phosphate 201Methotrexate 185Filgrastim 159Busulfan 147Etoposide 135Peripheral Blood Stem Cell Transplantation 133fludarabine 127Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 85Mycophenolic Acid 85Whole-Body Irradiation 80Melphalan 79Idarubicin 67Imatinib Mesylate 66Mercaptopurine 65Granulocyte Colony-Stimulating Factor 65Azacitidine 65Methylprednisolone 59Doxorubicin 58Prednisone 57Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Leukemia × immunotoxin HA22 × Clear all
NCT01891981 2023-10-13

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

M.D. Anderson Cancer Center

Phase 1 Terminated
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00587457 2017-07-06

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

MedImmune LLC

Phase 1 Terminated
11 enrolled 14 charts
LymphoidOther hematologic neoplasm

Cerebral Palsy, Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT00515892 2007-08-14

NHL

Cambridge Antibody Technology

Phase 1 Unknown
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin

NCT00462189 2007-04-18

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Recurrence

NCT00457860 2007-04-17

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Cambridge Antibody Technology

Phase 1 Unknown
50 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡